Clinical Report: A New Era of Targeted Treatment for TED
Overview
Recent advancements in understanding the pathophysiology of thyroid eye disease (TED) have led to the development of targeted biologic therapies, particularly IGF-1R antagonism. This approach represents a significant shift from traditional corticosteroid treatments, offering a disease-modifying option for patients.
Background
Thyroid eye disease is a challenging condition often associated with Graves disease, affecting a significant portion of patients and leading to debilitating symptoms. Traditional treatments have limitations, including high relapse rates and significant side effects. Understanding the underlying mechanisms of TED has paved the way for innovative therapies that target the disease's root causes.
Data Highlights
No numerical data available in the source material.
Key Findings
- Approximately 50% of patients with Graves disease develop TED, with a higher prevalence in women.
- Smoking is identified as the strongest modifiable risk factor for TED.
- Traditional treatments, including corticosteroids, provide limited relief and carry substantial risks.
- IGF-1R antagonism offers a promising new treatment strategy by targeting the underlying pathophysiology of TED.
- Disruption of IGF-1R signaling can block downstream effects of TSHR activation, providing a dual-target approach.
Clinical Implications
Clinicians should consider the role of IGF-1R antagonism in managing TED, particularly for patients with moderate-to-severe disease. Ongoing monitoring for potential side effects, such as hyperglycemia and hearing impairment, is essential during treatment.
Conclusion
The emergence of targeted therapies for TED marks a significant advancement in the management of this complex condition, offering hope for improved patient outcomes.
Related Resources & Content
- Ophthalmology Management, 2022 -- DIAGNOSE AND MANAGE THYROID EYE DISEASE Recommendations
- The Journal of Clinical Endocrinology & Metabolism, 2022 -- Management of Hyperthyroidism in Graves' Disease with Concurrent Thyroid Eye Disease Complications
- Ophthalmology Management, 2022 -- RX PERSPECTIVE
- European Journal of Endocrinology, 2021 -- 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines
- PubMed, 2018 -- Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO)
- The ASCO Post — Molecularly Targeted Therapy for Lung Cancer
- 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy | European Journal of Endocrinology | Oxford Academic
- Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial - PubMed
- Long-term Cardiovascular, Renal, and Safety Outcomes of Teprotumumab versus Systemic Glucocorticoids in Thyroid Eye Disease: A Target Trial Emulation - ScienceDirect
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.